# Belite Bio to Participate in Four Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/BLTE/belite-bio-to-participate-in-four-upcoming-investor-conferences-51ee4768
Ticker: BLTE
Company: Belite Bio
Source: Belite Bio
Published: 2026-09-01 12:00 EST
## Summary

Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company...

## Article Body
Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in four upcoming investor conferences. Details of the presentations are as follows:

Wells Fargo 21st Annual Healthcare Conference (Boston, MA) September 8, 2026, at 8:45 am ET, fireside chat

2026 Cantor Global Healthcare Conference (New York, NY) September 11, 2026, at 10:55 am ET, fireside chat

Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY) September 14, 2026, at 7:45 am ET, fireside chat

H.C. Wainwright 28th Annual Global Investment Conference (New Yok, NY) September 15, 2026, at 9:00 am ET, fireside chat

Webcast Link Instructions Webcasts of the presentations can be accessed under “Events” in the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events . The replays will be archived for 90 days following the presentation date.

About Belite Bio Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult subjects with STGD1, which met its primary endpoint, and the drug is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent and adult subjects with STGD1 and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X , Instagram , LinkedIn , and Facebook , or visit us at www.belitebio.com .

Media and Investor Relations Contacts: ir@belitebio.com
## Recent Company News
- 2026-09-01 12:00 EST — [Belite Bio to Participate in Four Upcoming Investor Conferences](https://biopharmsignal.com/news/BLTE/belite-bio-to-participate-in-four-upcoming-investor-conferences-51ee4768) — Source: Belite Bio
- 2026-08-24 20:00 EST — [Belite Bio to Host Virtual Commercial Day on September 2, 2026](https://biopharmsignal.com/news/BLTE/belite-bio-to-host-virtual-commercial-day-on-september-2-2026-46c4b01b) — Source: Belite Bio
- 2026-08-21 12:00 EST — [Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences](https://biopharmsignal.com/news/BLTE/belite-bio-announces-oral-presentations-at-two-upcoming-medical-conferences-a81706a3) — Source: Belite Bio
- 2026-08-13 01:45 EST — [Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update](https://biopharmsignal.com/news/BLTE/belite-bio-reports-unaudited-second-quarter-2026-financial-results-and-provides--70338f01) — Source: Belite Bio
- 2026-08-11 20:01 EST — [Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1](https://biopharmsignal.com/news/BLTE/belite-bio-announces-u-s-food-and-drug-administration-acceptance-and-priority-re-c1e12d07) — Source: Belite Bio
## Related News
- 2026-09-06 05:00 EST — ROIV — [Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call](https://biopharmsignal.com/news/ROIV/roivant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat--bf1ea553)
- 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd)
- 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f)
- 2026-09-04 20:05 EST — LIXT — [NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS](https://biopharmsignal.com/news/LIXT/nomad-power-solutions-announces-adjournment-of-special-meeting-of-stockholders-74cd9e2e)
- 2026-09-04 20:05 EST — AVTX — [Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-lis-cc7baaf2)